Open Respiratory Archives

Original article

Clinical Manifestations of Subjects With the Non-Specific Pulmonary Function Test Pattern

James Tasch [a],*, Samer Abujaber [a], Laith Hattar [b], Aju Jose [b], Lori Lyn Price [c], Peter LaCamera [a], Hernan Avella [a]

[a] *Division of Pulmonary, Critical Care and Sleep Medicine, Steward St. Elizabeth's Medical Center, Boston, MA, United States*
[b] *Department of Medicine, Steward St. Elizabeth's Medical Center, Boston, MA, United States*
[c] *Clinical and Translational Science Institute, Tufts University, Boston, MA, United States*

A R T I C L E   I N F O

A B S T R A C T

Introduction: Non-specific pattern (NSP) is a subgroup of preserved ratio impaired spirometry (PRISm) that requires a normal total lung capacity measurement. NSP has been historically classified as being an obstructive lung disease pattern. There has been heightened interest and investigation into PRISm recently as it has been associated with an increased likelihood of developing chronic obstructive pulmonary disease (COPD). Given the inherent challenges of understanding the clinical significance of the NSP, the aim of this study was to further explore the clinical characteristics of patients with this pulmonary function test pattern.
Material and methods: We identified 111 and 79 subjects using pre-bronchodilator (pre-BD) and post-bronchodilator (post-BD) values, respectively, that met criteria for NSP. The outpatient medical records were retrospectively reviewed for associated diagnoses that were then clustered into 'obstructive' or 'non-obstructive' groups based on the treating physician's primary pulmonary clinical diagnosis.
Results: Within this NSP cohort, cough, wheezing and sputum production were documented more frequently in those with an obstructive lung disease diagnosis. Whether identified using pre-BD or post-BD spirometric values, those with NSP and a positive BD response were more likely to carry an obstructive lung disease diagnosis.
Conclusion: Approximately one third of patients with NSP in this study were not given an obstructive lung disease diagnosis by their clinician, which supports the classification of NSP as not an exclusively obstructive lung disease pattern. However, the presence of supporting clinical symptoms, such as cough with sputum production and wheeze, and/or a positive BD response on PFT, support a diagnosis of obstruction in patients with NSP.

Manifestaciones clínicas de los pacientes con patrón inespecífico en las pruebas de la función pulmonar

R E S U M E N

Introducción: El patrón inespecífico constituye un subgrupo de alteraciones de la espirometría con conservación de la relación (PRISm, siglas en inglés) que precisa de una medición de la capacidad pulmonar total normal; históricamente se ha clasificado como un patrón de neumopatía obstructiva. En épocas recientes se ha intensificado el interés en las PRISm y su investigación, ya que se ha asociado a un aumento de la probabilidad de aparición de una enfermedad pulmonar obstructiva crónica (EPOC). Dadas las dificultades inherentes que conlleva interpretar la importancia clínica del patrón inespecífico, el objetivo de este estudio consistió en explorar con más detalle las características clínicas de los pacientes con dicho patrón en las pruebas de la función pulmonar.

* Corresponding author.
 E-mail address: James.Tasch@reliantmedicalgroup.org (J. Tasch).

Material y métodos: Se identificaron 111 y 79 sujetos empleando valores prebroncodilatador y posbroncodilatador, respectivamente, que cumplieron los criterios de patrón inespecífico. Se revisaron retrospectivamente las historias clínicas ambulatorias para detectar diagnósticos asociados que después se agregaron en grupos «obstructivos» o «no obstructivos» en función del diagnóstico clínico pulmonar primario del médico.

Resultados: En esta cohorte de pacientes con patrones inespecíficos, se documentó una mayor incidencia de tos, sibilancias y producción de esputo entre los que tenían un diagnóstico de neumopatía obstructiva. Los pacientes con patrón inespecífico y una respuesta positiva al broncodilatador, que hubiesen sido identificados con valores pre o posbroncodilatador, tenían más probabilidades de haber recibido un diagnóstico de neumopatía obstructiva.

Conclusión: Aproximadamente un tercio de los pacientes con patrón inespecífico de este estudio no habían recibido un diagnóstico de neumopatía obstructiva, dato que avala no clasificar los patrones inespecíficos exclusivamente en las neumopatías obstructivas. Sin embargo, la presencia de síntomas clínicos indicativos, como tos productiva y sibilancias, o una respuesta positiva al broncodilatador en las pruebas de la función pulmonar, sustenta un diagnóstico de obstrucción en los pacientes con patrón inespecífico.

Introduction

A pulmonary function test (PFT) is an invaluable tool in the evaluation of respiratory disease, and various PFT patterns have been identified using an algorithmic approach to help diagnose pulmonary disorders.[1,2] One such pattern is a normal forced exhalation volume in one second/forced vital capacity (FEV1/FVC) ratio with a reduced FEV1, which has been referred to as preserved ratio impaired spirometry (PRISm).[3] Non-specific pattern (NSP) can be thought of as a subgroup of PRISm that also includes a normal total lung capacity (TLC) measurement and was initially investigated in the 1990s by Hyatt et al.[4] These terms have been used interchangeably in much of the research in this field despite likely representing distinct patient populations.

There is growing research interest into PRISm given its high prevalence,[5,6] increased risk of all-cause mortality,[5,7–10] and association with the development of chronic obstructive pulmonary disease (COPD).[7,11,12] Clinical symptoms in patients with PRISm, such as wheezing, have been linked to the future development of COPD.[11] The same has not yet been described in NSP, though this pattern has been shown to remain stable or evolve into either obstructive or restrictive patterns over time.[13] Additionally, there lacks consensus on whether to use pre-BD or post-BD values in the definition of NSP, and whether a correlation exists between a positive BD response and a clinical diagnosis of obstructive lung disease in subjects with NSP.[13] Our aim was to explore the clinical characteristics and spirometric data associated with a clinician's diagnosis of obstructive lung disease in a population with NSP.

Material and methods

Study design

Data was retrospectively extracted from the Vmax™ Encore PFT System software at a single healthcare facility (Steward St. Elizabeth's Medical Center, Boston, MA, USA). Data for adult patients with complete or partial pulmonary function testing were included. PFT performance and PFT device maintenance followed American Thoracic Society and European Respiratory Society standardized techniques for quality assurance. Reference values and reference ranges for spirometry were calculated using the NHANES III equations[14] and they were extrapolated for subjects greater than 80 years old. A correction factor of 0.88 was applied for Asian-Americans.[15] European Respiratory Society equations[16] were used for lung volumes and they were extrapolated for subjects greater than 70 years old.

We retrospectively reviewed the medical record of subjects older than 18 years of age who demonstrated NSP on at least one PFT between 1/1/2014 and 7/1/2020. If a subject had multiple PFT's meeting inclusion criteria, only the earliest PFT was included. Study subjects were then separated into 'obstructive' or 'non-obstructive' groups based on the treating physician's primary pulmonary clinical diagnosis at the last known clinic visit that addressed pulmonary symptoms. This study was approved by the Institutional Review Board (IRB) at Steward St. Elizabeth's Medical Center in April 2021. The IRB determined that the authors met the regulatory requirements necessary in order to obtain a waiver of informed consent/authorization.

Definitions

NSP was defined as FEV1 and/or FVC being less than the lower limit of normal (LLN) but with both the FEV1/FVC ratio and TLC being greater than or equal to the LLN. Pre-BD spirometric values were used in the definition of NSP unless otherwise delineated. Two different criteria for determining a significant bronchodilator response were assessed and defined as follows: (Criteria A) an increase of greater than or equal to 12% from baseline FEV1 (and/or FVC) with a greater than or equal to 0.2 L in FEV1 (and/or FVC)[1,2] and (Criteria B) an increase of greater than 8% from reference in FEV1 (and/or FVC).[17] TLC was determined by either body plethysmography or nitrogen washout. The obstructive cohorts of study subjects were those given a diagnosis in the medical record of asthma, COPD, bronchiectasis, or a primary bronchiolar disorder such as bronchiolitis. The non-obstructive subjects were those assigned any other pulmonary diagnosis that was not included in the definition of obstructive lung disease. A "complete" PFT was one that included measurements of FEV1, FVC, FEV1/FVC ratio and TLC.

Data collection

De-identified study data were collected and managed using REDCap (Research Electronic Data Capture) tools hosted at Tufts University – Clinical and Translational Science Institute.[18,19]

Statistical analysis

The *t*-test was used to compare differences between groups where the data were normally distributed, while the non-parametric Wilcoxon rank sum test was used to compare differences where normality was not met. The Chi-square test or

Table 1
Demographics and clinical characteristics of study populations.

Variable	Non-obstructive diagnosis (*n* = 40)	Obstructive diagnosis (*n* = 71)	*P*-value
Age (years)	58.75 (13.72)[a]	59.38 (11.53)[a]	0.80
Body mass index (BMI)	29.61 (7.36)[a]	32.11 (32.11)[a]	0.16
Height (cm)	168.03 (9.57)[a]	166.27 (10.73)[a]	0.39
Sex			
Female	25 (62.50)	48 (67.61)	0.59
Male	15 (37.50)	23 (32.39)	
Symptoms			
Cough	13 (32.50)	41 (57.75)	0.01
Wheezing	5 (12.50)	25 (35.21)	0.01
Sputum production	0 (0.00)	13 (18.31)	0.004 FE
Hemoptysis	2 (5.00)	1 (1.41)	0.29 FE
Dyspnea at rest	4 (10.00)	4 (5.63)	0.46 FE
Dyspnea on exertion	21 (52.50)	43 (60.56)	0.41
Orthopnea	2 (5.00)	2 (2.82)	0.99 FE
Lower extremity edema	3 (7.50)	6 (8.45)	0.62 FE
Chest tightness	13 (32.50)	40 (56.34)	0.99 FE
Comorbidities			
Congestive heart failure	3 (7.50)	11 (15.49)	0.22
Coronary artery disease	7 (17.50)	11 (15.49)	0.78
Interstitial lung disease	3 (7.50)	2 (2.82)	0.35 FE
Autoimmune disease	4 (10.00)	5 (7.04)	0.72 FE
Hypertension	23 (57.50)	50 (70.42)	0.17
Lung cancer	7 (17.50)	4 (5.63)	0.05 FE
Diabetes mellitus	12 (30.00)	21 (29.58)	0.96
Chronic kidney disease	1 (2.50)	8 (11.27)	0.15 FE
Gastroesophageal reflux disease	11 (27.50)	27 (38.03)	0.26
Tobacco			
Never	15 (37.50)	18 (25.35)	0.16
Former	16 (40.00)	27 (38.03)	
Current	8 (20.00)	26 (36.62)	
Medications			
Proton pump inhibitor/H2 receptor antagonist	21 (52.50)	40 (56.34)	0.7
Leukotriene receptor antagonist	0 (0.00)	13 (18.31)	0.004 FE
Chronic steroids	5 (12.50)	4 (5.63)	0.28 FE
Biologics	0 (0.00)	2 (2.82)	0.53 FE
Alive as of 12/31/2020	35 (87.50)	65 (91.55)	0.52 FE
Follow up days	161 [0, 1033][b]	290 [46, 931][b]	0.34

Values are *N* (%). Asthma and COPD were both present in ~60% of patients in the obstructive group.

a Mean (SD)
b Median with 25/75th percentiles.

Fisher exact (FE) tests were used to test for associations between group and categorical variables.

Results

A total of 16,156 complete and partial PFTs were extracted for the study period between 1/1/2004 and 7/1/2020. Of those who had a complete study (*n* = 9447), 545 PFTs demonstrated NSP (prevalence of 5.8%). After excluding multiple PFTs from the same study subject (*n* = 9) and restricting the study period start date to 1/1/2014 (*n* = 11,059) to reflect the availability of the electronic medical record, 111 subjects with NSP were identified that met the final inclusion criteria. TLC was determined by body plethysmography in the majority (92%) of these 111 subjects.

Clinical symptoms in NSP

Of the 111 subjects demonstrating NSP, 71 (64%) were classified as obstructive based on the treating physician's primary pulmonary clinical diagnosis at the last known clinic visit that addressed pulmonary symptoms, while 40 (36%) were classified as non-obstructive. Compared to the non-obstructive group, cough, wheezing and sputum production were documented more frequently in those with an obstructive lung disease diagnosis (Table 1). There were significantly more inhalers listed in the

medication lists in the obstructive group. Notably, age, body mass index, tobacco use and residual volume (RV)/TLC ratio were not significantly different between groups.

Bronchodilator response

In those who met NSP criteria using either pre- or post-BD spirometry, having a significant BD response, using the standard definition 'Criteria A' ($\geq$12% change from baseline and $\geq$200 mL increase in FEV1 and/or FVC),[1] was associated with a clinical diagnosis of obstructive lung disease (Table 2). When using a previously published alternative definition of BD response 'Criteria B' (increase of >8% change from the predicted reference in FEV1 and/or FVC),[17] the association between a clinical obstructive diagnosis and BD response was only significant when using the post-BD NSP definition.

Subgroups of NSP

The NSP cohort was divided into subgroups based on subjects meeting criteria for NSP using pre- and post-BD spirometric values. Two pairs of subgroups were defined as follows: (Group A) subjects meeting NSP criteria with pre-BD values, but not with their post-BD values and (Group B) subjects meeting NSP criteria with post-BD values, but not with their pre-BD values (Table 3). Subjects in

Table 2

Demographics and PFT data for both NSP definitions using pre-BD and post-BD spirometric values, respectively.

Variable	Pre-bronchodilator NSP			Post-bronchodilator NSP		
	Non-obstructive diagnosis ($n = 40$)	Obstructive diagnosis ($n = 71$)	*P*-value	Non-obstructive diagnosis ($n = 24$)	Obstructive diagnosis ($n = 55$)	*P*-value
Age (years)	58.75 (13.72)[a]	59.38 (11.53)[a]	0.8	58.34 (9.82)[a]	59.21 (10.14)[a]	0.72
Body mass index (BMI)	29.61 (7.36)[a]	32.11 (9.72)[a]	0.16	31.44 (6.76)[a]	32.23 (8.91)[a]	0.7
Height (cm)	168.03 (9.57)[a]	166.27 (10.73)[a]	0.39	169.04 (9.87)[a]	164.80 (10.76)[a]	0.1
Sex						
Female	25 (62.50)	48 (67.61)	0.59	16 (66.67)	43 (78.18)	0.28
Male	15 (37.50)	23 (32.39)		8 (33.33)	12 (21.82)	
Tobacco						
Never	15 (37.50)	18 (25.35)	0.16	12 (50.00)	15 (27.27)	0.13
Former	16 (40.00)	27 (38.03)		7 (29.17)	20 (36.36)	
Current	8 (20.00)	26 (36.62)		5 (20.83)	20 (36.36)	
Bronchodilator response						
Criteria A (positive response)	2 (9.09)	17 (33.33)	0.03	0 (0.00)	15 (27.27)	0.004 FE
Criteria B (positive response)	4 (18.18)	17 (33.33)	0.19	1 (4.17)	14 (25.45)	0.03 FE

Values are *N* (%).

[a] Mean value (SD).

Discussion

Our study found a significant association between certain clinical characteristics and spirometric values and a clinician's diagnosis of obstructive lung disease in a cohort of study subjects with NSP. These results are informative given that the interpretation of NSP in clinical settings presents challenges for physicians both prognostically and therapeutically. In this study, nearly two thirds of patients with NSP carried a clinical diagnosis of obstructive lung disease and they were more likely to endorse classical symptoms consistent with this group of disorders – cough, sputum production and wheezing.

Approximately one third of patients with NSP in this study were not assigned an obstructive lung disease diagnosis by their treating physician and this highlights the uncertain nature of NSP and the broader diagnostic potential within this group. Given these findings, clinicians should strongly consider the clinical context and presence of supporting symptoms before assigning a fixed diagnosis to those with NSP.

While it is standard to use post-BD spirometric values in the definition of COPD,[20] the same has not been established for NSP. The role for the addition of a BD challenge with NSP was suggested by Pellegrino et al.,[1] but there is a lack of evidence in support of this. Iyer et al.[13] demonstrated that in those with NSP, a positive BD response, a history of smoking, and higher TLC – alveolar volume (VA) values were all predictors of the development of obstruction on a subsequent PFT when excluding specific airway resistance. Our study provides evidence that in those with NSP, whether identified using pre- or post-BD spirometry values, the presence of a positive BD response is associated with a clinical diagnosis of obstructive lung disease. This observation supports the importance of incorporating BD testing into standard PFT interpretation algorithms for those demonstrating NSP.

The clinical trajectory of patients with PRISm has been the subject of investigation in recent years,[7-9,21] specifically assessing whether new spirometric abnormalities are likely to develop on subsequent testing and whether patients can be recategorized when using different classification criterion. For example, Blagev et al.[22] showed that 20% of PFT's that originally demonstrated NSP were reclassified as obstructive when utilizing the largest measured vital capacity (VCmax) instead of the classically used FVC. To our knowledge, our study is the first attempt at clinically characterizing subgroups of patients based on the presence or absence of NSP in pre- and post-BD spirometric values. The clinical relevance of this grouping is unknown at this time, but identifying and describing such subgroups is a first step.

We advocate for utilizing precise definitions for PFT patterns of NSP and PRISm. They are similar but separate entities that should not be used interchangeably. The term PRISm should only be used when TLC data is unavailable. The use of detailed definitions becomes even more imperative with the emergence of the newer Global Lung Initiative (GLI) spirometric prediction equations[23] and the lack of consensus on whether to use pre- or post-BD spirometric values in the definition of NSP.

Despite a large PFT database, a large number of study subjects were excluded due to lack of access to electronic medical records prior to 1/1/2014. The study was also limited by its retrospective nature at a single acute care center as well as a relatively small sample size. Additionally, obstructive sleep apnea was not included as a relevant comorbidity in our cohort, which may have provided additional associations of interest. There were no obvious survival difference signals between the obstructive and non-obstructive groups, but diffusing capacity was not included in this study. A low diffusing capacity has been shown to be a significant risk factor for all-cause mortality in subjects with PRISm[24] so including diffusing capacity in future NSP studies is necessary. In retrospect, using the updated GLI reference equations would have been reasonable and even more astute given the potential for misinterpretation of PFT results and the inaccuracies with the older equations. Prospective studies involving NSP utilizing GLI equations are warranted.

In conclusion, this study demonstrated that subjects with NSP that carried an obstructive lung disease diagnosis (approximately two thirds of the study population) were more likely to be affected by symptoms consistent with this group of disorders, such as cough, wheezing and sputum production. It also supported the role of BD testing in subjects with NSP given that a positive response was associated with a clinical diagnosis of obstruction.

Group A either met criteria for obstruction or developed normal spirometry after BD administration, while subjects in Group B were reclassified from either obstruction or normal spirometry to NSP after BD administration.

Notation of prior abstract publication/presentation

This work has been presented in part at the Annual Research Day of Steward – St. Elizabeth's Medical Center, Boston, MA, USA (May

Table 3
Demographics and clinical characteristics of subgroup populations.

Variable	NSP using pre-BD values, but not in their post-BD values		NSP using post-BD values, but not in their pre-BD values	
	Became obstructed (n = 11)	Became normal (n = 15)	Were normal (n = 11)	Were obstructed (n = 22)
Age (years)	64.63 (7.11)[a]	56.08 (15.2)[a]	57.13 (8.8)[a]	57.85 (9.95)[a]
Body mass index (BMI)	28.62 (8.54)[a]	31.60 (10.75)[a]	31.76 (7.86)[a]	31.08 (6.29)[a]
Height (cm)	166.09 (9.21)[a]	171.67 (10.17)[a]	166.09 (13.74)[a]	168.68 (10.34)[a]
Sex				
Female	7 (63.64)	7 (46.67)	6 (54.55)	15 (68.18)
Male	4 (36.36)	8 (53.33)	5 (45.45)	7 (31.82)
Symptoms				
Cough	5 (45.45)	9 (60.00)	7 (63.64)	12 (54.55)
Wheezing	3 (27.27)	3 (20.00)	2 (18.18)	5 (22.73)
Sputum production	2 (18.18)	2 (13.33)	0 (0.00)	1 (4.55)
Hemoptysis	1 (9.09)	1 (6.67)	0 (0.00)	0 (0.00)
Dyspnea at rest	0 (0.00)	1 (6.67)	0 (0.00)	0 (0.00)
Dyspnea on exertion	4 (36.36)	11 (73.33)	4 (36.36)	10 (45.45)
Orthopnea	1 (9.09)	0 (0.00)	0 (0.00)	1 (4.55)
Lower extremity edema	0 (0.00)	0 (0.00)	1 (9.09)	2 (9.09)
Chest tightness	2 (18.18)	0 (0.00)	0 (0.00)	0 (0.00)
Comorbidities				
Congestive heart failure	1 (9.09)	2 (13.33)	1 (9.09)	1 (4.55)
Coronary artery disease	2 (18.18)	3 (20.00)	3 (27.27)	0 (0.00)
Interstitial lung disease	1 (9.09)	0 (0.00)	0 (0.00)	2 (9.09)
Autoimmune disease	1 (9.09)	2 (13.33)	1 (9.09)	0 (0.00)
Hypertension	8 (72.73)	9 (60.00)	9 (81.82)	7 (31.82)
Lung cancer	0 (0.00)	1 (6.67)	0 (0.00)	2 (9.09)
Diabetes mellitus	4 (36.36)	5 (33.33)	3 (27.27)	6 (27.27)
Chronic kidney disease	0 (0.00)	1 (6.67)	0 (0.00)	2 (9.09)
Gastroesophageal reflux disease	7 (63.64)	4 (26.67)	7 (63.64)	5 (22.73)
Tobacco				
Never	1 (9.09)	4 (26.67)	5 (45.45)	6 (30.00)
Former	6 (54.55)	9 (60.00)	3 (27.27)	7 (35.00)
Current	4 (36.36)	2 (13.33)	3 (27.27)	7 (35.00)
Medications				
Proton pump inhibitor/H2 receptor antagonist	5 (45.45)	8 (53.33)	10 (90.91)	7 (31.82)
Leukotriene receptor antagonist	2 (18.18)	1 (6.67)	0 (0.00)	3 (13.64)
Chronic steroids	0 (0.00)	2 (13.33)	1 (9.09)	0 (0.00)
Biologics	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
Alive as of 12/31/2020	11 (100.00)	14 (93.33)	11 (100.00)	16 (80.00)
Follow up days	139 [0, 931][b]	298 [70, 709][b]	369 [133, 706][b]	412 [38, 1142][b]

Values are N (%).
[a] Mean (SD).
[b] Median with 25/75th percentiles.

5, 2022), and the American Thoracic Society Annual Conference in San Francisco, CA, USA (May 13–18, 2022).

Authors' contributions

James Tasch: conceptualization, data curation/acquisition, formal analysis, writing – original draft, writing – review & editing.
Samer Abujaber: data acquisition, writing – review & editing.
Laith Hattar: data acquisition.
Aju Jose: data acquisition.
Lori Lyn Price: formal analysis, writing – review & editing.
Peter LaCamera: conceptualization, writing – review & editing.
Hernan Avella: conceptualization, data curation, writing – review & editing.

Conflicts of interest

All authors have no conflicts of interests to disclose that could have appeared to influence the work reported in this paper.

References

1. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68, http://dx.doi.org/10.1183/09031936.05.00035205. PMID: 16264058.

2. Stanojevic S, Kaminsky DA, Miller M, Thompson B, Aliverti A, Barjaktarevic I, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2021;23:2101499, http://dx.doi.org/10.1183/13993003.01499-2021. PMID: 34949706.

3. Wan ES, Castaldi PJ, Cho MH, Hokanson J, Regan E, Make B, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res. 2014;15–89, http://dx.doi.org/10.1186/s12931-014-0089-y. PMID: 25096860; PMCID: PMC4256936.

4. Hyatt RE, Scanlon PD, Nakamura M. Interpretation of pulmonary function tests: a practical guide. Rochester, MN: Lippincott-Raven; 1997. p. 13–37.

5. Wan ES, Fortis S, Regan EA, Hokanson J, MeiLan H, Casaburi R, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study. Am J Respir Crit Care Med. 2018;198:1397–405, http://dx.doi.org/10.1164/rccm.201804-0663OC. PMID: 29874098; PMCID: PMC6290948.

6. Schwartz A, Arnold N, Skinner B, Simmering J, Eberlein M, Comellas A, et al. Preserved ratio impaired spirometry in a spirometry database. Respir Care. 2021;66:58–65, http://dx.doi.org/10.4187/respcare.07712. Epub 2020 Sep 1. PMID: 32873751; PMCID: PMC7856524.

7. Wijnant SRA, De Roos E, Kavousi M, Stricker B, Terzikhan N, Lahousse L, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam study. Eur Respir J. 2020;55:1901217, http://dx.doi.org/10.1183/13993003.01217-2019. PMID: 31601717.

8. Marott JL, Ingebrigtsen TS, Çolak Y, Vestbo J, Lange P. Trajectory of preserved ratio impaired spirometry: natural history and long-term prognosis. Am J Respir Crit Care Med. 2021;204:910–20, http://dx.doi.org/10.1164/rccm.202102-0517OC. PMID: 34233141.

9. Higbee D, Granell R, Davey Smith G, Dodd J. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis. Lancet Respir Med. 2022;10:149–57, http://dx.doi.org/10.1016/S2213-2600(21)00369-6. Epub 2021 Nov 2. PMID: 34739861.

10. Wan ES, Balte P, Schwartz J, Bhatt S, Cassano P, Couper D, et al. Association between preserved ratio impaired spirometry and clinical outcomes in US adults. JAMA. 2021;326:2287–98, http://dx.doi.org/10.1001/jama.2021.20939. Erratum in: JAMA. 2022 Jan 18;327(3):286. PMID: 34905031; PMCID: PMC8672237.

11. Park HJ, Byun MK, Rhee CK, Kim K, Kim H, Yoo K. Significant predictors of medically diagnosed chronic obstructive pulmonary disease in patients with preserved ratio impaired spirometry: a 3-year cohort study. Respir Res. 2018;19:185, http://dx.doi.org/10.1186/s12931-018-0896-7. PMID: 30249256; PMCID: PMC6154818.

12. Fortis S, Comellas A, Kim V, Casaburi R, Hokanson J, Crapo J, et al. Low FVC/TLC in preserved ratio impaired spirometry (PRISm) is associated with features of and progression to obstructive lung disease. Sci Rep. 2020;10:5169, http://dx.doi.org/10.1038/s41598-020-61932-0. PMID: 32198360; PMCID: PMC7083974.

13. Iyer VN, Schroeder DR, Parker KO, Hyatt RE, Scanlon PD. The nonspecific pulmonary function test: longitudinal follow-up and outcomes. Chest. 2011;139:878–86, http://dx.doi.org/10.1378/chest.10-0804. Epub 2010 Aug 19. PMID: 20724741.

14. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179–87, http://dx.doi.org/10.1164/ajrccm.159.1.9712108. PMID: 9872837.

15. Hankinson JL, Kawut SM, Shahar E, Smith L, Stukovsky KH, Barr RG. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest. 2010;137:138–45, http://dx.doi.org/10.1378/chest.09-0919. Epub 2009 Sep 9. PMID: 19741060; PMCID: PMC2803123.

16. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, european community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40, http://dx.doi.org/10.1183/09041950.005s1693. PMID: 24576915.

17. Ward H, Cooper BG, Miller MR. Improved criterion for assessing lung function reversibility. Chest. 2015;148:877–86, http://dx.doi.org/10.1378/chest.14-2413. PMID: 25879725.

18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81, http://dx.doi.org/10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30. PMID: 18929686; PMCID: PMC2700030.

19. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software partners. J Biomed Inform. 2019;95:103208, http://dx.doi.org/10.1016/j.jbi.2019.103208. Epub 2019 May 9. PMID: 31078660; PMCID: PMC7254481.

20. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–46, http://dx.doi.org/10.1183/09031936.04.00014304. Erratum in: Eur Respir J. 2006 Jan; 27 (1) 242. PMID: 15219010.

21. Wan ES, Hokanson JE, Regan EA, Young K, Make B, DeMeo D, et al. Significant spirometric transitions and preserved ratio impaired spirometry among ever smokers. Chest. 2022;161:651–61, http://dx.doi.org/10.1016/j.chest.2021.09.021. Epub 2021 Sep 27. PMID: 34592319; PMCID: PMC8941606.

22. Blagev DP, Sorenson D, Linares-Perdomo O, Bamberg S, Hegewald M, Morris A. Evaluating how post-bronchodilator vital capacities affect the diagnosis of obstruction in pulmonary function tests. Respir Care. 2016;61:1523–9, http://dx.doi.org/10.4187/respcare.04611. Epub 2016 Sep 13. PMID: 27624631.

23. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Culver B, Enright P, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324–43, http://dx.doi.org/10.1183/09031936.00080312. Epub 2012 Jun 27. PMID: 22743675; PMCID: PMC3786581.

24. Ogata H, Sha K, Kotetsu Y, Enokizu-Ogawa A, Katahira K, Ishimatsu A, et al. The prognostic performance of lung diffusing capacity in preserved ratio impaired spirometry: an observational cohort study. Int J Chron Obstruct Pulmon Dis. 2022;17:2791–9, http://dx.doi.org/10.2147/COPD.S384074. PMID: 36339246; PMCID: PMC9627766.